ATE355826T1 - Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten - Google Patents

Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Info

Publication number
ATE355826T1
ATE355826T1 AT98957320T AT98957320T ATE355826T1 AT E355826 T1 ATE355826 T1 AT E355826T1 AT 98957320 T AT98957320 T AT 98957320T AT 98957320 T AT98957320 T AT 98957320T AT E355826 T1 ATE355826 T1 AT E355826T1
Authority
AT
Austria
Prior art keywords
nucleic acids
lipid
double layers
cells
lipid double
Prior art date
Application number
AT98957320T
Other languages
English (en)
Inventor
Edward G Saravolac
Yuan-Peng Zhang
Jeffery J Wheeler
Pieter R Cullis
Peter Scherrer
Ljiljana D Kojic
Olga Ludkovski
Original Assignee
Inex Pharmaceuticals Corp
Edward G Saravolac
Yuan-Peng Zhang
Jeffery J Wheeler
Pieter R Cullis
Peter Scherrer
Ljiljana D Kojic
Olga Ludkovski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp, Edward G Saravolac, Yuan-Peng Zhang, Jeffery J Wheeler, Pieter R Cullis, Peter Scherrer, Ljiljana D Kojic, Olga Ludkovski filed Critical Inex Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE355826T1 publication Critical patent/ATE355826T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98957320T 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten ATE355826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6347397P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE355826T1 true ATE355826T1 (de) 2007-03-15

Family

ID=22049444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957320T ATE355826T1 (de) 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Country Status (6)

Country Link
EP (1) EP1023048B1 (de)
AT (1) ATE355826T1 (de)
AU (1) AU1360499A (de)
CA (2) CA2309727C (de)
DE (1) DE69837274T2 (de)
WO (1) WO1999018933A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
JP5388395B2 (ja) * 1999-07-15 2014-01-15 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 脂質に被包された治療剤の製造方法
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
AU2000267686A1 (en) * 2000-08-10 2002-02-25 Applied Gene Technologies, Inc. Compositions and methods for nucleic acids sample processing and amplification
WO2002028367A1 (fr) 2000-10-04 2002-04-11 Kyowa Hakko Kogyo Co., Ltd. Procede de revetement de particules fines avec un film de lipides
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
NZ592917A (en) * 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉ｒｎａ
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
PL2245464T3 (pl) 2008-01-25 2017-08-31 Multivir Inc. Biomarkery p53
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (de) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
WO2011056682A1 (en) 2009-10-27 2011-05-12 The University Of British Columbia Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
TR201901311T4 (tr) 2009-12-01 2019-02-21 Translate Bio Inc İnsan genetik hastalıklarında mRNA'nın teslimi için steroid türevi.
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
CA2930973A1 (en) 2013-11-22 2015-05-28 Pal SAERTROM C/ebp alpha short activating rna compositions and methods of use
RU2620077C1 (ru) * 2015-11-26 2017-05-22 Ярославов А.А. Способ получения иммобилизованных бислойных везикул
EP4183882A1 (de) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Stabilisierte hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
EP3953473A1 (de) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna-zusammensetzungen und verfahren zur verwendung
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
EP4314292A1 (de) 2021-03-26 2024-02-07 MiNA Therapeutics Limited Tmem173-sarna-zusammensetzungen und verfahren zur verwendung
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5799996A (en) * 1995-05-26 1996-12-11 Cell Genesys, Inc. Delivery vehicles comprising stable lipid/nucleic acid compl exes
EP1489184A1 (de) * 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Herstellung von Lipid-nukleinsäure Partikeln duch ein hydrophobische Lipid-nukleinsäuree Komplexe Zwischenprodukt und zur Verwendung in der Gentransfer

Also Published As

Publication number Publication date
CA2792406A1 (en) 1999-04-22
DE69837274T2 (de) 2007-11-08
CA2309727A1 (en) 1999-04-22
WO1999018933A2 (en) 1999-04-22
EP1023048B1 (de) 2007-03-07
WO1999018933A3 (en) 1999-07-01
EP1023048A1 (de) 2000-08-02
CA2309727C (en) 2012-12-04
DE69837274D1 (de) 2007-04-19
AU1360499A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
ATE355826T1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DE69534760D1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
NO20014231L (no) Innkapsling av bioaktive komplekser i liposomer
ZA95137B (en) Composition containing nucleic acids preparation and use
ATE272393T1 (de) Rekonstruktion gereinigter membranproteine in vorgefertigten liposomen
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
DE93619T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
WO2000011176A3 (en) Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
WO2003063785A3 (en) Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
DE60028152D1 (de) Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung
HUT43106A (en) Dns sequences koding proteins of flesh-i type inhibitor activity and process for producing these proteins
BG101379A (en) New pypimido [1,2-a] indoles
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE353368T1 (de) Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen
DE69900653D1 (de) Verfahren zur Herstellung von Säuregruppen enthaltenden Bisxylenolen
AR013801A1 (es) Nuevas moleculas de acido nucleico aislada, una proteina de epoxido hidrolasa de artropodo hematofago aislada, una formulacion de proteinas deepoxido hidrolasa de pulga, una composicion terapeutica que reduce la infestacion de ectoparasitos hematofagos; uso de dicha composicion para la
WO2002074922A3 (en) Compositions and methods for modulating an immune response
FI20000956A0 (fi) Kosmeettinen tai ihonhoidollinen voidekoostumus, sen valmistusmenetelmä ja käyttö
WO1999059638A8 (en) Compositions and methods for the delivery of nucleic acid molecules
IT8821189A0 (it) Di estere fosforico dell'acido ursodeossicolico e suoi derivati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principi attivi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties